Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study
Open Access
- 27 November 2024
- Vol. 9 (12) , 103968
Abstract
No abstract availableKeywords
Funding Information
- PharmaMar SA
This publication has 11 references indexed in Scilit:
- Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastasesLung Cancer, 2023
- Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world studyLung Cancer, 2023
- Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung CancerClinical Lung Cancer, 2023
- What Is New in Small Cell Lung CancerHematology/Oncology Clinics of North America, 2023
- Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapyRespiratory Medicine and Research, 2023
- Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialThe Lancet Respiratory Medicine, 2022
- SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancerTranslational Lung Cancer Research, 2021
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialThe Lancet Oncology, 2020
- A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 TrialJournal of Thoracic Oncology, 2019